{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T07:00:31Z","timestamp":1784962831469,"version":"3.55.0"},"reference-count":103,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T00:00:00Z","timestamp":1784937600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T00:00:00Z","timestamp":1784937600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"CIHR Pan-Canadian Network for HIV and STBBI Clinical Trials Research (CTN+) Postdoctoral Fellowship award."},{"name":"Canada Research Chair in Biomedical HIV\/STI Prevention"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr HIV\/AIDS Rep"],"DOI":"10.1007\/s11904-026-00793-0","type":"journal-article","created":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T04:26:27Z","timestamp":1784953587000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["HSV, HIV, and Pregnancy: Epidemiology, Viral Interactions, Management, and Prevention"],"prefix":"10.1007","volume":"23","author":[{"given":"Sheliza","family":"Halani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark H.","family":"Yudin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darrell H. S.","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,25]]},"reference":[{"issue":"9","key":"793_CR1","doi-asserted-by":"publisher","first-page":"3321","DOI":"10.1128\/JCM.39.9.3321-3325.2001","volume":"39","author":"JA Ribes","year":"2001","unstructured":"Ribes JA, Steele AD, Seabolt JP, Baker DJ. Six-Year Study of the Incidence of Herpes in Genital and Nongenital Cultures in a Central Kentucky Medical Center Patient Population. J Clin Microbiol. 2001;39(9):3321\u20135.","journal-title":"J Clin Microbiol"},{"issue":"8","key":"793_CR2","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1001\/jama.2010.1206","volume":"304","author":"B Pasternak","year":"2010","unstructured":"Pasternak B, Hviid A. Use of Acyclovir, Valacyclovir, and Famciclovir in the First Trimester of Pregnancy and the Risk of Birth Defects. JAMA. 2010;304(8):859\u201366.","journal-title":"JAMA"},{"issue":"4","key":"793_CR3","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1002\/bdra.20013","volume":"70","author":"K Stone","year":"2004","unstructured":"Stone K, Reiff-Eldridge R, White A, Cordero J, Brown Z, Alexander E, et al. Pregnancy outcomes following systemic prenatal acyclovir exposure: Conclusions from the international acyclovir pregnancy registry, 1984\u20131999. Birth Defects Res Part A: Clin Mol Teratology. 2004;70(4):201\u20137.","journal-title":"Birth Defects Res Part A: Clin Mol Teratology"},{"key":"793_CR4","doi-asserted-by":"crossref","unstructured":"Bekker LG, Das M, Abdool Karim Q, Ahmed K, Batting J, Brumskine W et al. Twice-Yearly Lenacapavir or Daily F\/TAF for HIV Prevention in Cisgender Women. NEJM. 2024.","DOI":"10.1056\/NEJMoa2407001"},{"key":"793_CR5","unstructured":"EACS Guidelines. 2023. European AIDS Clinical Society. 2023:1-162."},{"issue":"41","key":"793_CR6","doi-asserted-by":"publisher","first-page":"E1374","DOI":"10.1503\/cmaj.250511","volume":"197","author":"DHS Tan","year":"2025","unstructured":"Tan DHS, Hull MW, Onyegbule SO, Ajiboye W, Arkell C, Baril J-G, et al. Canadian guideline on HIV pre- and postexposure prophylaxis: 2025 update. CMAJ. 2025;197(41):E1374\u201391.","journal-title":"CMAJ"},{"key":"793_CR7","unstructured":"CDC. Clinical Guidance for PrEP 2025. Available from: https:\/\/www.cdc.gov\/hivnexus\/hcp\/prep\/index.html. Accessed 26 January 2026."},{"key":"793_CR8","volume-title":"testing strategies for long-acting injectable pre-exposure prophylaxis (PrEP)","author":"Guidelines on lenacapavir for HIV prevention and","year":"2025","unstructured":"Guidelines on lenacapavir for HIV prevention and. testing strategies for long-acting injectable pre-exposure prophylaxis (PrEP). Geneva: World Health Organization; 2025. Contract No.: License: CC BY-NC-SA 3.0 IGO."},{"key":"793_CR9","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1016\/S1473-3099(17)30405-X","volume":"17","author":"KJ Looker","year":"2017","unstructured":"Looker KJ, Elmes JAR, Gottlieb SL, Schiffer JT, Vickerman P, Turner KME, et al. Effect of HSV-2 infection on subsequent HIV acquisition: an updated systematic review and meta-analysis. Lancet. 2017;17:1303\u201316.","journal-title":"Lancet"},{"key":"793_CR10","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1086\/589621","volume":"198","author":"N Nagot","year":"2008","unstructured":"Nagot N, Oudraogo A, Konate I, Weiss HA, Foulongne V, Defer MC, et al. Herpes Simplex Virus Type 2 Infection and Human Immunodeficiency Virus Type 1 (HIV-1)\u2013Induced Immunosuppression on Genital and Plasma HIV-1 Levels. J Infect Dis. 2008;198:241\u20139.","journal-title":"J Infect Dis"},{"issue":"6","key":"793_CR11","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1111\/j.1468-1293.2010.00896.x","volume":"12","author":"C Barde","year":"2011","unstructured":"Barde C, Piguet v, Pech\u00e8re M, Masouye I, Saurat J-H, Wunderli W, et al. Management of resistant mucocutaneous herpes simplex infections in AIDS patients: a clinical and virological challenge. HIV Med. 2011;12(6):367\u201373.","journal-title":"HIV Med"},{"issue":"5","key":"793_CR12","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1016\/j.chom.2017.04.007","volume":"21","author":"N Arora","year":"2017","unstructured":"Arora N, Sadovsky Y, Dermody TS, Coyne CB. Microbial vertical transmission during human pregnancy. Cell Host Microbe. 2017;21(5):561\u20137.","journal-title":"Cell Host Microbe"},{"key":"793_CR13","unstructured":"Genital herpes guide. Risk factors and clinical manifestations Public Health Agency of Canada, Government of Canada 2021. Available from: https:\/\/www.canada.ca\/en\/public-health\/services\/infectious-diseases\/sexual-health-sexually-transmitted-infections\/canadian-guidelines\/herpes-simplex-virus\/risk-factors-clinical-manifestation.html. Accessed 25 January 2026."},{"issue":"6","key":"793_CR14","doi-asserted-by":"publisher","first-page":"433","DOI":"10.7326\/0003-4819-116-6-433","volume":"116","author":"DM Koelle","year":"1992","unstructured":"Koelle DM, Benedetti J, Langenberg A, Corey L. Asymptomatic Reactivation of Herpes Simplex Virus in Women after the First Episode of Genital Herpes. Ann Intern Med. 1992;116(6):433\u20137.","journal-title":"Ann Intern Med"},{"issue":"2","key":"793_CR15","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1093\/infdis\/jiq035","volume":"203","author":"W Phipps","year":"2011","unstructured":"Phipps W, Saracino M, Magaret A, Selke S, Remington M, Huang M-L, et al. Persistent Genital Herpes Simplex Virus-2 Shedding Years Following the First Clinical Episode. J Infect Dis. 2011;203(2):180\u20137.","journal-title":"J Infect Dis"},{"issue":"5","key":"793_CR16","doi-asserted-by":"publisher","first-page":"106636","DOI":"10.1016\/j.jinf.2025.106636","volume":"91","author":"S Andreu","year":"2025","unstructured":"Andreu S, Galdo-Torres D, Ripa I, Caballero O, Bello-Morales R, L\u00f3pez-Guerrero JA. From HSV-2 to HSV-1: A change in the epidemiology of genital herpes. J Infect. 2025;91(5):106636.","journal-title":"J Infect"},{"key":"793_CR17","doi-asserted-by":"publisher","first-page":"100876","DOI":"10.1016\/j.eclinm.2021.100876","volume":"35","author":"M Harfouche","year":"2021","unstructured":"Harfouche M, Abu-Hijleh FM, James C, Looker KJ, Abu-Raddad LJ. Epidemiology of herpes simplex virus type 2 in sub-Saharan Africa: Systematic review, meta-analyses, and meta-regressions. EClinicalMedicine. 2021;35:100876.","journal-title":"EClinicalMedicine"},{"key":"793_CR18","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1136\/sextrans-2021-054972","volume":"97","author":"M Harfouche","year":"2021","unstructured":"Harfouche M, Maalmi H, Abu-Raddad LJ. Epidemiology of herpes simplex virus type 2 in Latin America and the Caribbean: systematic review, meta- analyses and metaregressions. Sex Transm Infect. 2021;97:490\u2013500.","journal-title":"Sex Transm Infect"},{"key":"793_CR19","doi-asserted-by":"publisher","first-page":"100558","DOI":"10.1016\/j.lanepe.2022.100558","volume":"25","author":"A Alareeki","year":"2023","unstructured":"Alareeki A, Osman AMM, Khandakji MN, Looker KJ, Harfouche M, Abu-Raddad LJ. Epidemiology of herpes simplex virus type 2 in Europe: systematic review, meta-analyses, and meta-regressions. Lancet Reg Health - Europe. 2023;25:100558.","journal-title":"Lancet Reg Health - Europe"},{"issue":"10","key":"793_CR20","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1093\/cid\/ciy318","volume":"67","author":"ME Patton","year":"2018","unstructured":"Patton ME, Bernstein K, Liu G, Zaidi A, Markowitz LE. Seroprevalence of Herpes Simplex Virus Types 1 and 2 Among Pregnant Women and Sexually Active, Nonpregnant Women in the United States. Clin Infect Dis. 2018;67(10):1535\u201342.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"793_CR21","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1007\/s40980-025-00136-4","volume":"13","author":"M Evans","year":"2025","unstructured":"Evans M, Newmyer L. A State-Level Examination into Structural Racism and Racialized Disparities in Sexually Transmitted Infections. Spat Demography. 2025;13(1):4.","journal-title":"Spat Demography"},{"issue":"7","key":"793_CR22","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1089\/jwh.2015.5637","volume":"25","author":"C Prather","year":"2016","unstructured":"Prather C, Fuller TR, Marshall KJ, Jeffries WL. The Impact of Racism on the Sexual and Reproductive Health of African American Women. J Womens Health (Larchmt). 2016;25(7):664\u201371.","journal-title":"J Womens Health (Larchmt)"},{"key":"793_CR23","first-page":"1","volume":"304","author":"GM McQuillan","year":"2018","unstructured":"McQuillan GM, Kruszon-Moran D, Flagg EW, Paulose-Ram R. Prevalence of Herpes Simplex Virus Type 1 and Type 2 in Persons Aged 14\u201349: United States, 2015\u20132016. NCHS Brief Data. 2018;304:1\u20138.","journal-title":"NCHS Brief Data"},{"key":"793_CR24","doi-asserted-by":"publisher","first-page":"525","DOI":"10.5694\/j.1326-5377.1993.tb121867.x","volume":"158","author":"AL Cunningham","year":"1993","unstructured":"Cunningham AL, Lee FK, Ho DW, Field PR, Law CL, Packham DR, et al. Herpes simplex virus type 2 antibody in patients attending antenatal or STD clinics. Med J Australia. 1993;158:525\u20138.","journal-title":"Med J Australia"},{"key":"793_CR25","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1136\/sti.75.3.168","volume":"75","author":"M Arvaja","year":"1999","unstructured":"Arvaja M, Lehtinen M, Koskela P, Lappalainen M, Paavonen J, Vesikari T. Serological evaluation of herpes simplex virus type 1 and type 2 infections in pregnancy. Sex Transm Inf. 1999;75:168\u201371.","journal-title":"Sex Transm Inf"},{"issue":"1","key":"793_CR26","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1186\/s12879-017-2674-4","volume":"17","author":"JW Domercant","year":"2017","unstructured":"Domercant JW, Louis FJ, Hulland E, Griswold M, Andre-Alboth J, Ye T, et al. Seroprevalence of Herpes Simplex Virus type-2 (HSV-2) among pregnant women who participated in a national HIV surveillance activity in Haiti. BMC Infect Dis. 2017;17(1):577.","journal-title":"BMC Infect Dis"},{"key":"793_CR27","doi-asserted-by":"crossref","unstructured":"Radoi CL, Cristea OM, Vulcanescu DD, Voinescu A, Dragomir TL, Sima LV et al. Seroprevalence of Herpes Simplex Virus Types 1 and 2 among Pregnant Women in South-Western Romania. Life. 2024(5):596.","DOI":"10.3390\/life14050596"},{"key":"793_CR28","doi-asserted-by":"publisher","first-page":"157680","DOI":"10.1155\/2011\/157680","volume":"2011","author":"J Patterson","year":"2011","unstructured":"Patterson J, Hitti J, Selke S, Huang M-L, Watts DH, Brown Z, et al. Genital HSV Detection among HIV-1-Infected Pregnant Women in Labor. Infect Dis Obstet Gynecol. 2011;2011:157680.","journal-title":"Infect Dis Obstet Gynecol"},{"issue":"1","key":"793_CR29","doi-asserted-by":"publisher","first-page":"19","DOI":"10.4103\/jgid.jgid_56_18","volume":"11","author":"CG Anaedobe","year":"2019","unstructured":"Anaedobe CG, Ajani TA. Co-infection of Herpes Simplex Virus Type 2 and HIV Infections among Pregnant Women in Ibadan, Nigeria. J Global Infect Dis. 2019;11(1):19\u201324.","journal-title":"J Global Infect Dis"},{"issue":"5","key":"793_CR30","doi-asserted-by":"publisher","first-page":"e193","DOI":"10.1097\/AOG.0000000000003840","volume":"135","author":"Management of Genital Herpes in Pregnancy","year":"2020","unstructured":"Management of Genital Herpes in Pregnancy. ACOG Practice Bulletinacog Practice Bulletin, Number 220. Obstet Gynecol. 2020;135(5):e193\u2013202.","journal-title":"Obstet Gynecol"},{"issue":"1","key":"793_CR31","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/0002-9378(82)90686-X","volume":"143","author":"LA Vontver","year":"1982","unstructured":"Vontver LA, Hickok DE, Brown Z, Reid L, Corey L. Recurrent genital herpes simplex virus infection in pregnancy: infant outcome and frequency of asymptomatic recurrences. Am J Obstet Gynecol. 1982;143(1):75\u201384.","journal-title":"Am J Obstet Gynecol"},{"key":"793_CR32","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1097\/OLQ.0000000000001458","volume":"48","author":"JS Slutsker","year":"2021","unstructured":"Slutsker JS, Schillinger JA. Assessing the Burden of Infant Deaths Due to Herpes Simplex Virus, Human Immunodeficiency Virus, and Congenital Syphilis: United States, 1995 to 2017. Sex Transm Dis. 2021;48:S4\u201310.","journal-title":"Sex Transm Dis"},{"issue":"4","key":"793_CR33","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1097\/OLQ.0000000000002094","volume":"52","author":"MM Azqul","year":"2025","unstructured":"Azqul MM, Griner SB, Pinto CN. Congenital Syphilis in the US: A Narrative Review. Sex Transm Dis. 2025;52(4):211\u20136.","journal-title":"Sex Transm Dis"},{"key":"793_CR34","unstructured":"Infectious syphilis and congenital syphilis in Canada. 2023: Public Health Agency of Canada. 2024. Available from: https:\/\/publications.gc.ca\/collections\/collection_2025\/aspc-phac\/HP37-48-2023-eng.pdf. Accessed 7 May 2026."},{"key":"793_CR35","doi-asserted-by":"publisher","first-page":"385697","DOI":"10.1155\/2012\/385697","volume":"2012","author":"G Straface","year":"2012","unstructured":"Straface G, Selmin A, Zanardo V, De Santis M, Ercoli A, Scambia G. Herpes Simplex Virus Infection in Pregnancy. Infect Dis Obstet Gynecol. 2012;2012:385697.","journal-title":"Infect Dis Obstet Gynecol"},{"issue":"4","key":"793_CR36","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1093\/pch\/19.4.201","volume":"19","author":"UD Allen","year":"2020","unstructured":"Allen UD, Robinson JL, Bitnun A, McDonald J, Society CP. Prevention and management of neonatal herpes simplex virus infections. Paediatr Child Health. 2020;19(4):201\u201312.","journal-title":"Paediatr Child Health"},{"issue":"18","key":"793_CR37","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1056\/NEJM199105023241804","volume":"324","author":"ZA Brown","year":"1991","unstructured":"Brown ZA, Benedetti J, Ashley R, Burchett S, Selke S, Berry S, et al. Neonatal herpes simplex virus infection in relation to asymptomatic maternal infection at the time of labor. NEJM. 1991;324(18):1247\u201352.","journal-title":"NEJM"},{"issue":"20","key":"793_CR38","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1056\/NEJM198711123172002","volume":"317","author":"ZA Brown","year":"1987","unstructured":"Brown ZA, Vontver LA, Benedetti J, Critchlow CW, Sells CJ, Berry S, et al. Effects on infants of a first episode of genital herpes during pregnancy. NEJM. 1987;317(20):1246\u201351.","journal-title":"NEJM"},{"key":"793_CR39","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/j.ajog.2005.08.018","volume":"194","author":"KE Mark","year":"2006","unstructured":"Mark KE, Kim HN, Wald A, Gardella C, Reed SD. Targeted prenatal herpes simplex virus testing: Can we identify women at risk of transmission to the neonate? Am J Obstet Gynecol. 2006;194:408\u201314.","journal-title":"Am J Obstet Gynecol"},{"issue":"5","key":"793_CR40","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1080\/00016340601151949","volume":"86","author":"EL Brown","year":"2007","unstructured":"Brown EL, Gardella C, Malm G, Prober CG, Forsgren M, Krantz EM, et al. Effect of maternal herpes simplex virus (HSV) serostatus and HSV type on risk of neonatal herpes. Acta Obstet et Gynecol. 2007;86(5):523\u20139.","journal-title":"Acta Obstet et Gynecol"},{"key":"793_CR41","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1053\/j.semperi.2018.02.004","volume":"42","author":"SG Pinninti","year":"2018","unstructured":"Pinninti SG, Kimberlin DW. Neonatal herpes simplex virus infections. Semin Perinatol. 2018;42:168\u201375.","journal-title":"Semin Perinatol"},{"issue":"4","key":"793_CR42","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/0029-7844(95)00457-2","volume":"87","author":"ZA Brown","year":"1996","unstructured":"Brown ZA, Benedetti J, Selke S, Ashley R, Watts H, Corey L. Asymptomatic Maternal Shedding of Herpes Simplex Virus at the Onset of Labor: Relationship to Preterm Labor. Obstet Gynecol. 1996;87(4):483\u20138.","journal-title":"Obstet Gynecol"},{"issue":"2","key":"793_CR43","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1067\/mob.2000.105967","volume":"183","author":"DJ Rouse","year":"2000","unstructured":"Rouse DJ, Stringer JSA. An appraisal of screening for maternal type-specific herpes simplex virus antibodies to prevent neonatal herpes. Am J Obstet Gynecol. 2000;183(2):400\u20136.","journal-title":"Am J Obstet Gynecol"},{"issue":"4","key":"793_CR44","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1111\/jdv.20450","volume":"39","author":"R Patel","year":"2024","unstructured":"Patel R, Moran B, Clarke E, Geretti AM, Lautenschlager S, Green J, et al. 2024 European guidelines for the management of genital herpes. J Eur Acad Dermatology Venereology: JEADV. 2024;39(4):742\u201358.","journal-title":"J Eur Acad Dermatology Venereology: JEADV"},{"issue":"8","key":"793_CR45","doi-asserted-by":"publisher","first-page":"e199","DOI":"10.1016\/j.jogc.2017.04.016","volume":"39","author":"D Money","year":"2017","unstructured":"Money D, Steben M. 208-Guidelines for the Management of Herpes Simplex Virus in Pregnancy. J Obstet Gynecol Can. 2017;39(8):e199\u2013205.","journal-title":"J Obstet Gynecol Can"},{"key":"793_CR46","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1086\/515385","volume":"178","author":"M Reitano","year":"1998","unstructured":"Reitano M, Tyring S, Lang W, Thoming C, Worm A-M, Borelli S, et al. Valaciclovir for the Suppression of Recurrent Genital Herpes Simplex Virus Infection: A Large-Scale Dose Range-Finding Study. J Infect Dis. 1998;178:603\u201310.","journal-title":"J Infect Dis"},{"issue":"1","key":"793_CR47","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1097\/01.AOG.0000219749.96274.15","volume":"108","author":"JS Sheffield","year":"2006","unstructured":"Sheffield JS, Hill JB, Hollier LM, Laibl VR, Roberts SW, Sanchez PK, et al. Valacyclovir prophylaxis to prevent recurrent herpes at delivery: a randomized clinical trial. Obstet Gynecol. 2006;108(1):141\u20137.","journal-title":"Obstet Gynecol"},{"issue":"3","key":"793_CR48","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1067\/mob.2003.185","volume":"188","author":"DH Watts","year":"2003","unstructured":"Watts DH, Brown ZA, Money D, Selke S, Huang M-L, Sacks SL, et al. A double-blind, randomized, placebo-controlled trial of acyclovir in late pregnancy for the reduction of herpes simplex virus shedding and cesarean delivery. Am J Obstet Gynecol. 2003;188(3):836\u201343.","journal-title":"Am J Obstet Gynecol"},{"issue":"1","key":"793_CR49","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1177\/09564624241280734","volume":"36","author":"E Clarke","year":"2024","unstructured":"Clarke E, Patel R, Dickins D, Fidler K, Jackson A, Kingston M, et al. Joint British Association for Sexual Health and HIV and Royal College of Obstetricians and Gynaecologists national UK guideline for the management of herpes simplex virus (HSV) in pregnancy and the neonate (2024 update). Int J STD AIDS. 2024;36(1):4\u201323.","journal-title":"Int J STD AIDS"},{"key":"793_CR50","unstructured":"Annual report 2022\u20132023 British Paediatric Surveillance Unit. 2023. Available from: https:\/\/www.rcpch.ac.uk\/work-we-do\/bpsu\/annual-reports. Accessed 7 May 2026."},{"key":"793_CR51","doi-asserted-by":"crossref","unstructured":"Hollier L, Wendel G. Third trimester antiviral prophylaxis for preventing maternal genital herpes simplex virus (HSV) recurrences and neonatal infection. Cochrane Database Syst Reviews. 2008(1).","DOI":"10.1002\/14651858.CD004946.pub2"},{"key":"793_CR52","unstructured":"HIV data and statistics: World Health Orgnization. 2025. Available from: https:\/\/www.who.int\/teams\/global-hiv-hepatitis-and-stis-programmes\/hiv\/strategic-information\/hiv-data-and-statistics. Accessed 20 November 2025."},{"issue":"44","key":"793_CR53","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/MD.0000000000040339","volume":"103","author":"NA Shabbir","year":"2024","unstructured":"Shabbir NA, Kant SB, Rashid K, Hafeez U, Akbar AA, Batool SW, et al. Prevalence of HIV\/AIDS among pregnant women in North American region: A systematic review and meta-analysis. Med (Baltim). 2024;103(44):1\u201312.","journal-title":"Med (Baltim)"},{"key":"793_CR54","unstructured":"Kufa-Chakezha T, Shangase N, Lombard C, Manda S, Puren A. The 2022 Antenatal HIV Sentinel Survey: Key Findings 2022. Available from: https:\/\/www.nicd.ac.za\/wp-content\/uploads\/2024\/01\/Antenatal-survey-2022-report_National_Provincial_12Jul2023_Clean_01.pdf. Accessed 8 April 2025."},{"issue":"4","key":"793_CR55","doi-asserted-by":"publisher","first-page":"849","DOI":"10.3390\/v15040849","volume":"15","author":"M Camila Cardenas","year":"2022","unstructured":"Camila Cardenas M, Farnan S, Hamel BL, Mejia Plazas MC, Sintim-Aboagye E, Littlefield DR, et al. Prevention of the Vertical Transmission of HIV; A Recap of the Journey so Far. Viruses. 2022;15(4):849.","journal-title":"Viruses"},{"issue":"1","key":"793_CR56","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.jogc.2017.06.033","volume":"40","author":"M Loutfy","year":"2018","unstructured":"Loutfy M, Kennedy VL, Poliquin V, Dzineku F, Dean NL, Margolese S, et al. 354-Canadian HIV Pregnancy Planning Guidelines. J Obstet Gynecol Can. 2018;40(1):94\u2013114.","journal-title":"J Obstet Gynecol Can"},{"issue":"2","key":"793_CR57","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1590\/S0036-46652014000200008","volume":"56","author":"MFM Barral","year":"2014","unstructured":"Barral MFM, de Oliveira GR, Lobato RC, Mendoza-Sassi RA, Martinez AMB, Goncalves CV. Risk Factors of HIV-1 Vertical Transmission (VT) and the Influence of Antiretroviral Therapy (ART) in Pregnancy Outcome. Rev Inst Med Trop Sao Paulo. 2014;56(2):133\u20138.","journal-title":"Rev Inst Med Trop Sao Paulo"},{"issue":"3","key":"793_CR58","doi-asserted-by":"publisher","first-page":"e590","DOI":"10.1093\/cid\/ciac703","volume":"76","author":"J Sibiude","year":"2023","unstructured":"Sibiude J, Le Chenadec J, Mandelbrot L, Hoctin A, Dollfus C, Faye A, et al. Update of Perinatal Human Immunodeficiency Virus Type 1 Transmission in France: Zero Transmission for 5482 Mothers on Continuous Antiretroviral Therapy From Conception and With Undetectable Viral Load at Delivery. Clin Infect Dis. 2023;76(3):e590\u20138.","journal-title":"Clin Infect Dis"},{"key":"793_CR59","unstructured":"Guidelines for the Prevention of Mother-to-, Child HIV, Transmission. OHTN 2017. Available from: https:\/\/www.ohtn.on.ca\/wp-content\/uploads\/2019\/04\/MTCT-prevention-guidelines-January-20-2017.pdf. Accessed 4 April 2025."},{"key":"793_CR60","doi-asserted-by":"crossref","unstructured":"Atkinson A, Tulloch K, Boucoiran I, Money D, Guideline. No. 450: Care of Pregnant Women Living with HIV and Interventions to Reduce Perinatal Transmission. Society of Obstetricians and Gynecologists of Canada. 2024;46(6):102551.","DOI":"10.1016\/j.jogc.2024.102551"},{"key":"793_CR61","volume-title":"Interventions to Reduce Perinatal HIV Transmission in the United States","author":"Recommendations for the Use of Antiretroviral Drugs During Pregnancy and","year":"2026","unstructured":"Recommendations for the Use of Antiretroviral Drugs During Pregnancy and. Interventions to Reduce Perinatal HIV Transmission in the United States. Rockville, MD: Department of Health and Human Services; 2026."},{"issue":"13","key":"793_CR62","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1056\/NEJM199904013401301","volume":"340","author":"W Andiman","year":"1999","unstructured":"Andiman W, Bryson Y, de Martino M, Fowler M, Harris D, Hutto C, et al. The mode of delivery and the risk of vertical transmission of human immunodeficiency virus type 1\u2013a meta-analysis of 15 prospective cohort studies. N Engl J Med. 1999;340(13):977\u201387.","journal-title":"N Engl J Med"},{"issue":"2","key":"793_CR63","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1097\/00002030-199802000-00011","volume":"12","author":"C Kind","year":"1998","unstructured":"Kind C, Rudin C, Siegrist C-A, Wyler C-A, Biedermann K, Lauper U, et al. Prevention of vertical HIV transmission: additive protective effect of elective Cesarean section and zidovudine prophylaxis. AIDS. 1998;12(2):205\u201310.","journal-title":"AIDS"},{"key":"793_CR64","doi-asserted-by":"crossref","unstructured":"Mofenson LM, Lambert JS, Stiehm R, Bethel J, Meyer WA III, Whitehouse J et al. Risk factors for perinatal trnsmission of human immunodeficiency virus type 1 in women treated with zidovudine NEJM. 1999;341(6):385\u201393.","DOI":"10.1056\/NEJM199908053410601"},{"key":"793_CR65","first-page":"101248","volume":"53","author":"A Kelly-Hanku","year":"2024","unstructured":"Kelly-Hanku A, Songtaweesin WN, Palmares ML, Bartlett AW, Gare J, Sta Maria MK, et al. The urgency of now to end HIV vertical transmission for pregnant and breastfeeding women and their children in Asia and the Pacific. Lancet Reg Health West Pac. 2024;53:101248.","journal-title":"Lancet Reg Health West Pac"},{"issue":"1","key":"793_CR66","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1891\/1058-1243.20.1.61","volume":"20","author":"S Wood","year":"2011","unstructured":"Wood S. Answering Questions About Herpes in Pregnancy. J Perinat Educ. 2011;20(1):61\u20134.","journal-title":"J Perinat Educ"},{"key":"793_CR67","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/S1473-3099(08)70181-6","volume":"8","author":"P Van de Perre","year":"2008","unstructured":"Van de Perre P, Segondy M, Foulongne V, Ouedraogo A, Konate I, Huraux J-M, et al. Herpes simplex virus and HIV-1: deciphering viral synergy. Lancet Infect Dis. 2008;8:490\u20137.","journal-title":"Lancet Infect Dis"},{"key":"793_CR68","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1097\/QAD.0b013e328012b896","volume":"21","author":"A Rebbapragada","year":"2007","unstructured":"Rebbapragada A, Wachihi C, Pettengell C, Sunderji S, Huibner S, Jaoko W, et al. Negative mucosal synergy between Herpes simplex type 2 and HIV in the female genital tract. AIDS. 2007;21:589\u201398.","journal-title":"AIDS"},{"key":"793_CR69","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/S1473-3099(19)30470-0","volume":"20","author":"KJ Looker","year":"2020","unstructured":"Looker KJ, Welton NJ, Sabin KM, Dalal S, Vickerman P, Turner KME, et al. Global and regional estimates of the contribution of herpes simplex virus type 2 infection to HIV incidence: a population attributable fraction analysis using published epidemiological data. Lancet Infect Dis. 2020;20:240\u20139.","journal-title":"Lancet Infect Dis"},{"issue":"10","key":"793_CR70","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1086\/587697","volume":"197","author":"PM Sheth","year":"2008","unstructured":"Sheth PM, Sunderji S, Shin LYY, Rebbapragada A, Huibner S, Kimani J, et al. Coinfection with Herpes Simplex Virus Type 2 Is Associated with Reduced HIV-Specific T Cell Responses and Systemic Immune Activation. J Infect Dis. 2008;197(10):1394\u2013401.","journal-title":"J Infect Dis"},{"issue":"3","key":"793_CR71","doi-asserted-by":"publisher","first-page":"228","DOI":"10.2174\/157016212800618156","volume":"102","author":"RV Barnabas","year":"2012","unstructured":"Barnabas RV, Celum C. Infectious Co-factors in HIV-1 transmission Herpes Simplex Virus type-2 and HIV-1: New Insights and interventions. Curr HIV Res. 2012;102(3):228\u201337.","journal-title":"Curr HIV Res"},{"key":"793_CR72","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1016\/S0140-6736(00)04331-2","volume":"357","author":"RH Gray","year":"2001","unstructured":"Gray RH, Wawer MJ, Brookmeyer R, Sewankambo N, Serwadda D, Wabwire-Mangen F, et al. Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda. Lancet. 2001;357:1149\u201353.","journal-title":"Lancet"},{"issue":"5","key":"793_CR73","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1056\/NEJMoa0904849","volume":"362","author":"C Celum","year":"2010","unstructured":"Celum C, Wald A, Lingappa J, Magaret AS, Wang RS, Mugo N, et al. Acyclovir and Transmission of HIV-1 from Persons Infected with HIV-1 and HSV-2. NEJM. 2010;362(5):427\u201339.","journal-title":"NEJM"},{"key":"793_CR74","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1136\/sti.75.2.98","volume":"75","author":"A Kamali","year":"1999","unstructured":"Kamali A, Nunn AJ, Mulder DW, Van Dyck E, Dobbins JG, Whitworth JAG. Seroprevalence and incidence of genital ulcer infections in a rural Ugandan population. Sex Transm Infect. 1999;75:98\u2013102.","journal-title":"Sex Transm Infect"},{"key":"793_CR75","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1086\/315076","volume":"180","author":"W McFarland","year":"1999","unstructured":"McFarland W, Gwanzura L, Bassett MT, Machekano R, Latif AS, Ley C, et al. Prevalence and Incidence of Herpes Simplex Virus Type 2 Infection among Male Zimbabwean Factory Workers. J Infect Dis. 1999;180:1459\u201365.","journal-title":"J Infect Dis"},{"issue":"5","key":"793_CR76","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1097\/00126334-200404150-00001","volume":"35","author":"L Corey","year":"2004","unstructured":"Corey L, Wald A, Celum CL, Quinn TC. The Effects of Herpes Simplex Virus-2 on HIV-1 Acquisition and Transmission: A Review of Two Overlapping Epidemics. J Acquir Immune Defic Syndr. 2004;35(5):435\u201345.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"793_CR77","doi-asserted-by":"crossref","unstructured":"Walton S, Madaric S, Oxenius A. CD4 T cell responses in latent and chronic viral infections. Front Immunol. 2013;4(105).","DOI":"10.3389\/fimmu.2013.00105"},{"issue":"11","key":"793_CR78","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1097\/00002030-199211000-00012","volume":"6","author":"EK Bagdades","year":"1992","unstructured":"Bagdades EK, Pillay D, Squire SB, O\u2019Neil C, Johnson MA, Griffiths PD. Relationship between herpes simplex virus ulceration and CD4\u2009+\u2009cell counts in patients with HIV infection. AIDS. 1992;6(11):1317\u201320.","journal-title":"AIDS"},{"issue":"11","key":"793_CR79","doi-asserted-by":"publisher","first-page":"845","DOI":"10.7326\/0003-4819-123-11-199512010-00006","volume":"123","author":"M Augenbraun","year":"1995","unstructured":"Augenbraun M, Feldman J, Chirgwin K, Zenilman J, Clarke L, DeHovitz J, et al. Increased genital shedding of herpes simplex virus type 2 in HIV-seropositive women. Ann Intern Med. 1995;123(11):845\u20137.","journal-title":"Ann Intern Med"},{"issue":"1","key":"793_CR80","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.jri.2007.02.002","volume":"77","author":"R Kaul","year":"2008","unstructured":"Kaul R, Pettengell C, Sheth PM, Sunderji S, Biringer A, MacDonald K, et al. The genital tract immune milieu: an important determinant of HIV susceptibility and secondary transmission. J Reprod Immunol. 2008;77(1):32\u201340.","journal-title":"J Reprod Immunol"},{"issue":"5","key":"793_CR81","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1093\/infdis\/jit252","volume":"208","author":"AAR Tobian","year":"2013","unstructured":"Tobian AAR, Grabowski MK, Serwadda D, Newell K, Ssebbowa P, Franco V, et al. Reactivation of Herpes Simplex Virus Type 2 After Initiation of Antiretroviral Therapy. J Infect Dis. 2013;208(5):839\u201346.","journal-title":"J Infect Dis"},{"key":"793_CR82","unstructured":"Services UDoHaH. Sexually Transmitted Infections Treatment Guidelines. 2021. MMWR US Department of Health and Human Services; 2021."},{"key":"793_CR83","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.ijid.2015.02.002","volume":"33","author":"C Leeyaphan","year":"2015","unstructured":"Leeyaphan C, Surawan TM, Chirachanakul P, Prasertworonun N, Punyaratabandhu P, Omchareon V, et al. Clinical characteristics of hypertrophic herpes simplex genitalis and treatment outcomes of imiquimod: a retrospective observational study. Int J Infect Dis. 2015;33:165\u201370.","journal-title":"Int J Infect Dis"},{"issue":"5","key":"793_CR84","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1093\/infdis\/jiz203","volume":"220","author":"MJ Keller","year":"2019","unstructured":"Keller MJ, Huber A, Espinoza L, Serrano MG, Parikh HI, Buck GA, et al. Impact of Herpes Simplex Virus Type 2 and Human Immunodeficiency Virus Dual Infection on Female Genital Tract Mucosal Immunity and the Vaginal Microbiome. J Infect Dis. 2019;220(5):852\u201361.","journal-title":"J Infect Dis"},{"key":"793_CR85","doi-asserted-by":"crossref","unstructured":"Yudin MH, Kaul R. Progrssive Hypertrophic Genital Herpes in an HIV-Infected Woman despite Immune Recovery on Antiretroviral Therapy. Infect Dis Obstet Gynecol. 2008:592532.","DOI":"10.1155\/2008\/592532"},{"issue":"1","key":"793_CR86","doi-asserted-by":"publisher","first-page":"5","DOI":"10.4103\/0974-2727.176228","volume":"8","author":"A Munawwar","year":"2016","unstructured":"Munawwar A, Singh S. Human Herpesviruses as Copathogens of HIV Infection, Their Role in HIV Transmission, and Disease Progression. J Lab physicians. 2016;8(1):5\u201318.","journal-title":"J Lab physicians"},{"issue":"1","key":"793_CR87","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1128\/JCM.42.1.242-249.2004","volume":"42","author":"C Danve-Szatanek","year":"2004","unstructured":"Danve-Szatanek C, Aymard M, Thouvenot D, Morfin F, Agius G, Bertin I, et al. Surveillance Network for Herpes Simplex Virus Resistance to Antiviral Drugs: 3-Year Follow-Up. J Clin Microbiol. 2004;42(1):242\u20139.","journal-title":"J Clin Microbiol"},{"issue":"8","key":"793_CR88","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1136\/sextrans-2016-052921","volume":"93","author":"V Sivarajah","year":"2017","unstructured":"Sivarajah V, Venus K, Yudin MH, Murphy KE, Morrison SA, Tan DHS. Does maternal HSV-2 coinfection increase mother-to-child transmission of HIV? A systematic review. Sex Transm Infect. 2017;93(8):535\u201342.","journal-title":"Sex Transm Infect"},{"key":"793_CR89","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1093\/infdis\/jiv495","volume":"213","author":"AJ Low","year":"2015","unstructured":"Low AJ, Nagot N, Weiss HA, Konate I, Kania D, Segondy M, et al. Herpes Simplex Virus Type-2 Cervicovaginal Shedding Among Women Living With HIV-1 and Receiving Antiretroviral Therapy in Burkina Faso: An 8-Year Longitudinal Study. J Infect Dis. 2015;213:731\u20137.","journal-title":"J Infect Dis"},{"issue":"10337","key":"793_CR90","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1016\/S0140-6736(22)00538-4","volume":"399","author":"S Delany-Moretlwe","year":"2022","unstructured":"Delany-Moretlwe S, Hughes JP, Bock P, Ouma SG, Hunidzarira P, Kalonji D, et al. Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial. Lancet. 2022;399(10337):1779\u201389.","journal-title":"Lancet"},{"key":"793_CR91","unstructured":"Guidelines for HIV post-exposure prophylaxis2024."},{"issue":"3","key":"793_CR92","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.idc.2020.06.013","volume":"34","author":"K Thakarar","year":"2020","unstructured":"Thakarar K, Nenninger K, Agmas W. Harm Reduction Services to Prevent and Treat Infectious Diseases in People Who Use Drugs. Infect Dis Clin N Am. 2020;34(3):605\u201320.","journal-title":"Infect Dis Clin N Am"},{"issue":"1","key":"793_CR93","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa035144","volume":"350","author":"L Corey","year":"2004","unstructured":"Corey L, Wald A, Patel R, Sacks SL, Tyring SK, Warren T, et al. Once-Daily Valacyclovir to Reduce the Risk of Transmission of Genital Herpes. NEJM. 2004;350(1):11\u201320.","journal-title":"NEJM"},{"issue":"2","key":"793_CR94","doi-asserted-by":"publisher","first-page":"37","DOI":"10.14745\/ccdr.v42i02a03","volume":"42","author":"CR Smith","year":"2016","unstructured":"Smith CR, Pogany L, Auguste U, Steben M, Lau TTY. Does suppressive antiviral therapy for herpes simplex virus prevent transmission in an HIV-positive population? A systematic review. CCDR. 2016;42(2):37\u201344.","journal-title":"CCDR"},{"key":"793_CR95","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1093\/infdis\/jit333","volume":"208","author":"A Mujugira","year":"2013","unstructured":"Mujugira A, Magaret A, Celum S, Baeten C, Lingappa JM, Morrow JR. Daily Acyclovir to Decrease Herpes Simplex Virus Type 2 (HSV-2) Transmission from HSV- 2\/HIV-1 Coinfected Persons: A Randomized Controlled Trial. J Infect Dis. 2013;208:1366\u201374.","journal-title":"J Infect Dis"},{"issue":"12","key":"793_CR96","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.1086\/593214","volume":"198","author":"JM Baeten","year":"2008","unstructured":"Baeten JM, Strick LB, Lucchetti A, Whittington WLH, Sanchez J, Coombs RW, et al. Herpes Simplex Virus Suppressive Therapy Decreases Plasma and Genital HIV-1 Levels in HSV-2\/HIV-1 Co-infected Women: A Randomized, Placebo-Controlled, Cross-Over Trial. J Infect Dis. 2008;198(12):1804\u20138.","journal-title":"J Infect Dis"},{"key":"793_CR97","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1093\/jac\/dky433","volume":"74","author":"D Tan","year":"2019","unstructured":"Tan D, Raboud JM, Szadkowski L, Grinsztejn B, Madruga J, Figueroa M, et al. Effect of valaciclovir on CD4 count decline in untreated HIV: an international randomized controlled trial. J Antimicrob Chemother. 2019;74:480\u20138.","journal-title":"J Antimicrob Chemother"},{"key":"793_CR98","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/S0140-6736(11)61750-9","volume":"379","author":"C Johnston","year":"2012","unstructured":"Johnston C, Saracino M, Kuntz S, Magaret A, Selke S, Huang M-L. Standard-dose and high-dose daily antiviral therapy for short episodes of genital HSV-2 reactivation: three randomised, open-label, cross-over trials. Lancet. 2012;379:641\u20137.","journal-title":"Lancet"},{"issue":"3","key":"793_CR99","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1056\/NEJMoa1301150","volume":"370","author":"A Wald","year":"2014","unstructured":"Wald A, Corey L, Timmler B, Magaret A, Warren T, Tyring S, et al. Helicase\u2013Primase Inhibitor Pritelivir for HSV-2 Infection. N Engl J Med. 2014;370(3):201\u201310.","journal-title":"N Engl J Med"},{"issue":"23","key":"793_CR100","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1001\/jama.2016.18189","volume":"316","author":"A Wald","year":"2016","unstructured":"Wald A, Timmler B, Magaret A, Warren T, Tyring S, Johnston C, et al. Effect of Pritelivir Compared With Valacyclovir on Genital HSV-2 Shedding in Patients With Frequent Recurrences A Randomized Clinical Trial. JAMA. 2016;316(23):2495\u2013503.","journal-title":"JAMA"},{"issue":"10","key":"793_CR101","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/ofid\/ofac494","volume":"9","author":"M Kawashima","year":"2022","unstructured":"Kawashima M, Imafuku S, Fujio K, Komazaki H. Single-Dose, Patient-Initiated Amenamevir Therapy for Recurrent Genital Herpes: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study. Open Forum Infect Dis. 2022;9(10):1\u20138.","journal-title":"Open Forum Infect Dis"},{"issue":"12","key":"793_CR102","doi-asserted-by":"publisher","first-page":"2625","DOI":"10.1007\/s12325-017-0642-4","volume":"34","author":"T Kuswake","year":"2017","unstructured":"Kuswake T, Keirns JJ, Kowalski D, den Adel M, Groenendaal-van de Meent D, Takada A, et al. Pharmacokinetics and Safety of Amenamevir in Healthy Subjects: Analysis of Four Randomized Phase 1 Studies. Adv Therapy. 2017;34(12):2625\u201337.","journal-title":"Adv Therapy"},{"issue":"8","key":"793_CR103","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1097\/OLQ.0000000000001342","volume":"48","author":"DHS Tan","year":"2021","unstructured":"Tan DHS, Tavanagar F, Fusca L, Ross P, Hull MW, Grennan T, et al. Interest in Hypothetical Preexposure Prophylaxis Against Herpes Simplex Virus: A Cross-Sectional Survey. Sex Transm Dis. 2021;48(8):105\u20138.","journal-title":"Sex Transm Dis"}],"container-title":["Current HIV\/AIDS Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11904-026-00793-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11904-026-00793-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11904-026-00793-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T06:01:54Z","timestamp":1784959314000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11904-026-00793-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,25]]},"references-count":103,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["793"],"URL":"https:\/\/doi.org\/10.1007\/s11904-026-00793-0","relation":{},"ISSN":["1548-3576"],"issn-type":[{"value":"1548-3576","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,25]]},"assertion":[{"value":"28 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All reported studies\/experiments with human or animal participants performed by the authors have been previously published and complied with all applicable ethical standards (including the Helsinki declaration and its amendments, institutional\/national research committee standards, and international\/national\/institutional guidelines).","order":1,"name":"Ethics","label":"Human and Animal Rights and Informed Consent statement","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. Darrell Tan reports funds from Gilead Sciences Inc. for investigator-initiated research, funds from Glaxo Smith Kline to Dr. Tan\u2019s institution for participation in industry-sponsored research, and funds to Dr. Tan\u2019s institution from Viiv Healthcare for participation in industry-sponsored research. Dr. Darrell Tan is supported by a Canada Research Chair in Biomedical HIV\/STI Prevention. Dr. Sheliza Halani received support from the CIHR Pan-Canadian Network for HIV and STBBI Clinical Trials Research (CTN+) Postdoctoral Fellowship award.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"24"}}